Stuart Hughes, Pathios Therapeutics CEO

Bris­tol My­ers pitch­es in to Pathios’ $25M Se­ries B for GPCR in­hibitor

Pathios Ther­a­peu­tics drew in $25 mil­lion for the first close of a Se­ries B raise that should help the UK biotech test its first-in-class sol­id …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.